Vertex Pharmaceuticals Incorporated: Hepatitis C trials

The registry lists 29 Hepatitis C studies with Vertex Pharmaceuticals Incorporated as lead sponsor. 0 are open to participants now and 12 have results posted.

Phase 1 10Phase 2 16Phase 3 4Phase 4 1No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C VirusTerminatedNCT01701063Phase 1/2Results posted
• An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant PatientsTerminatedNCT01467505Phase 2Results posted
• Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis CTerminatedNCT01467492Phase 4Results posted
• A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)TerminatedNCT01467479Phase 3Results posted
• Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC GenotypeTerminatedNCT01459913Phase 3Results posted
• Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIVCompletedNCT00983853Phase 2Results posted
• A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral ResponseCompletedNCT00758043Phase 3Results posted
• A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)CompletedNCT00627926Phase 3Results posted
• A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to TherapyCompletedNCT00535847Phase 2Results posted
• A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)CompletedNCT00420784Phase 2Results posted
• Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis CCompletedNCT00372385Phase 2Results posted
• Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis CCompletedNCT00336479Phase 2Results posted
• A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis CCompletedNCT01842451Phase 2
• A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis CCompletedNCT01726946Phase 2
• VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis CCompletedNCT01581138Phase 2
• A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated CirrhosisCompletedNCT01516918Phase 2
• A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy SubjectsCompletedNCT01511432Phase 1
• Drug-Drug Interaction Study Between Telaprevir and BuprenorphineCompletedNCT01275599Phase 1
• Study of VX-985 in Subjects With Chronic Hepatitis CCompletedNCT01144936Phase 1
• A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus InfectionTerminatedNCT01080222Phase 2
• A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy AdultsCompletedNCT01038167Phase 1
• Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy SubjectsCompletedNCT00958152Phase 1
• Virology Follow up Study in Subjects Previously Treated With TelaprevirCompletedNCT00916474
• Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C InfectionCompletedNCT00911963Phase 1/2
• Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C InfectionCompletedNCT00623649Phase 1
• A Proof-of-concept Study of VCH-759 for the Treatment of Hepatitis C-infection.CompletedNCT00389298Phase 1/2
• Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis CCompletedNCT00262483Phase 2
• VX-950 and Peginterferon for Hepatitis CCompletedNCT00251199Phase 1
• Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis CCompletedNCT00088504Phase 2